To assess the potential clinical utility of CPL304110, in vivo efficacy in two patient-derived xenograft models was evaluated with confirmed FGFR2 amplification, i.e., in a non-small cell lung cancer PDTX model LU6429 and a gastric PDTX model GA1224. This evidence concerns the gene FGFR2 and non-small cell lung carcinoma.